Press "esc" to clear
Go to Advanced Search

Showing results

110 of 644

Article ID: 696093

American Society for Radiation Oncology (ASTRO) to host 60th Annual Meeting in San Antonio, October 21-24

American Society for Radiation Oncology (ASTRO)

The American Society for Radiation Oncology (ASTRO) will host its 60th Annual Meeting at the Henry B. Gonzalez Convention Center in San Antonio, October 18-24, 2018. The meeting will feature updates from clinical trials and cancer research involving radiation therapy, and keynote addresses from Ned Sharpless, MD, Director of the National Cancer Institute and Yukiya Amano, Director General of the International Atomic Energy Agency .

Released:
14-Jun-2018 2:40 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 694358

More Clinical Trials Should Combine Radiation Therapy with Promising New Cancer Drugs

American Society for Radiation Oncology (ASTRO)

The American Society for Radiation Oncology (ASTRO) today issued the following statement in support of findings from an ASTRO-commissioned task force to review opportunities to improve outcomes for cancer patients by expanding the number of clinical trials that include radiation therapy in combination with new cancer drugs. The recommendations were published in the May 2018 issue of The Lancet-Oncology.

Released:
10-May-2018 3:45 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
HowardSandler.jpg

Article ID: 694272

Experts Available to Discuss New USPSTF Prostate Cancer Screening Guidelines

American Society for Radiation Oncology (ASTRO)

Released:
9-May-2018 1:40 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 691954

Updated ASTRO Guideline for Palliative Lung Radiation Now Recommends Concurrent Chemotherapy for Some Stage III Patients

American Society for Radiation Oncology (ASTRO)

The American Society for Radiation Oncology (ASTRO) today issued an update to its clinical guideline for the use of palliative-intent radiation therapy for patients with incurable non-small cell lung cancer (NSCLC). Reflecting new evidence from randomized clinical trials, the guideline now recommends the addition of concurrent chemotherapy to radiation therapy for certain patients with incurable stage III NSCLC, including those who are able to tolerate chemotherapy and have a life expectancy longer than three months.

Released:
4-Apr-2018 8:30 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    12-Mar-2018 5:00 PM EDT

Article ID: 690828

ASTRO Issues Clinical Guideline for Whole Breast Radiation Therapy

American Society for Radiation Oncology (ASTRO)

The American Society for Radiation Oncology (ASTRO) today issued a new clinical guideline for the use of whole breast radiation therapy for breast cancer that expands the population of patients recommended to receive accelerated treatment known as hypofractionated therapy.

Released:
8-Mar-2018 5:00 PM EST
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    13-Feb-2018 12:00 PM EST

Article ID: 689416

Phase II Trial Demonstrates Activity of Durvalumab in Patients with Recurrent or Metastatic Head and Neck Cancer

American Society for Radiation Oncology (ASTRO)

Analysis of the phase II CONDOR trial indicates that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic head and neck cancer and has the potential to slow growth in tumors with low or negative expression of the PD-L1 protein.

Released:
13-Feb-2018 7:05 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    13-Feb-2018 12:00 PM EST

Article ID: 689417

Nivolumab Immunotherapy Safe and Feasible During Chemoradiation for Advanced Head and Neck Cancer

American Society for Radiation Oncology (ASTRO)

Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck cancers.

Released:
13-Feb-2018 7:05 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    13-Feb-2018 12:00 PM EST

Article ID: 689421

Lower-Dose Radiation Therapy Effective and Safe for HPV-Related Head and Neck Cancer After Induction Chemotherapy, Trial Finds

American Society for Radiation Oncology (ASTRO)

Results of the phase II OPTIMA clinical trial indicate that patients with head and neck cancers associated with the human papillomavirus (HPV), including those with advanced nodal disease, can receive substantially lower radiation doses safely and effectively if they respond to induction chemotherapy initially.

Released:
13-Feb-2018 8:05 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    13-Feb-2018 12:05 AM EST

Article ID: 689418

Cabozantinib Shows Significant Activity in the First Line for Differentiated Thyroid Cancer

American Society for Radiation Oncology (ASTRO)

Results of a new phase II clinical trial indicate that cabozantinib offers an active therapy option for patients with differentiated thyroid cancer (DTC) that has progressed following surgery and treatment with radioactive iodine (RAI). Thirty-four of 35 patients in the trial experienced a reduction in tumor size following treatment with the targeted kinase inhibitor, and more than half experienced reductions in excess of 30 percent.

Released:
13-Feb-2018 7:05 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 687176

ASTRO Applauds Congressional Leaders for Extending the Radiation Oncology Payment Freeze

American Society for Radiation Oncology (ASTRO)

The American Society for Radiation Oncology (ASTRO) today applauded congressional leaders for the passage of legislation to freeze payment rates for key radiation oncology services delivered in freestanding clinics.

Released:
9-Feb-2018 7:55 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment

Showing results

110 of 644





Chat now!